晚期尿路上皮癌-话题@MedSci

#晚期尿路上皮癌#

30篇内容 | 1196人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189849, encodeId=5918218984914, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a> <a href='/topic/show?id=341f25314f1' target=_blank style='color:#2F92EE;'>#仑伐替尼#</a> <a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a>, objectTitle=EUR UROL | 帕博利珠单抗伴或不伴仑伐替尼作为晚期尿路上皮癌患者的一线治疗（LEAP-011）:一项3期、随机、双盲试验, objectType=article, longId=815040, objectId=b6ca81504034, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240227/1709040431897_6145188.jpg, objectUrl=/article/show_article.do?id=b6ca81504034, replyNumber=0, likeNumber=0, createdTime=2024-02-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b6ca81504034, moduleTitle=EUR UROL | 帕博利珠单抗伴或不伴仑伐替尼作为晚期尿路上皮癌患者的一线治疗（LEAP-011）:一项3期、随机、双盲试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6ca81504034)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2157359, encodeId=3f53215e3594c, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a> 随着过去几年批准用于治疗局部晚期或转移性尿路上皮癌（UC）的新型药物的可用性，了解长期随访期间治疗的潜在益处和风险对于医生和患者来说是至关重要的信息。转移性膀胱癌患者的5年相对生存率约为6%。最常见的膀胱癌形式是UC，占所有病例的90%以上。对于在用程序性细胞死亡蛋白1/配体1（PD-1）抑制剂，化疗或两者治疗期间或之后经历疾病进展的局部晚期或转移性UC患者，需要新的有效治疗，特别是那些具有长期总生存期（OS）和安全性数据的治疗。, objectTitle=晚期尿路上皮癌, objectType=topic, longId=59825, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=24, createdTime=2023-09-12, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2156413, encodeId=b535215641357, content=<a href='/topic/show?id=ec3210659347' target=_blank style='color:#2F92EE;'>#恩福单抗#</a>（EV）加<a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a>治疗<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Nat Rev Clin Oncol | 恩福单抗（EV）加帕博利珠单抗治疗晚期尿路上皮癌, objectType=article, longId=790462, objectId=108fe904624a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230906/1693980742761_6145188.jpg, objectUrl=/article/show_article.do?id=108fe904624a, replyNumber=0, likeNumber=37, createdTime=2023-09-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=108fe904624a, moduleTitle=Nat Rev Clin Oncol | 恩福单抗（EV）加帕博利珠单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=108fe904624a)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1440261, encodeId=310214402615a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=47, createdTime=2022-04-20, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440260, encodeId=207a1440260f3, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, objectType=article, longId=300810, objectId=d19e300810ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19e300810ee, replyNumber=0, likeNumber=42, createdTime=2022-03-16, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19e300810ee, moduleTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19e300810ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440259, encodeId=666d1440259a9, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌, objectType=article, longId=299225, objectId=42b329922588, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42b329922588, replyNumber=0, likeNumber=42, createdTime=2022-02-21, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42b329922588, moduleTitle=Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42b329922588)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440258, encodeId=97c41440258b4, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=The Oncologist：在使用免疫检查点抑制剂治疗的晚期尿路上皮癌患者中，身体成分可作为独立的预测和预后标志物, objectType=article, longId=215463, objectId=64ca21546318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ca21546318, replyNumber=0, likeNumber=40, createdTime=2021-08-10, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ca21546318, moduleTitle=The Oncologist：在使用免疫检查点抑制剂治疗的晚期尿路上皮癌患者中，身体成分可作为独立的预测和预后标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64ca21546318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440257, encodeId=abc9144025eff, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=晚期尿路上皮癌新疗法在 2 期临床试验中显示出前景, objectType=article, longId=215231, objectId=9b2521523195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b2521523195, replyNumber=0, likeNumber=34, createdTime=2021-08-05, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b2521523195, moduleTitle=晚期尿路上皮癌新疗法在 2 期临床试验中显示出前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b2521523195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440256, encodeId=1cb414402561b, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, objectType=article, longId=211950, objectId=274d2119505a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=274d2119505a, replyNumber=0, likeNumber=30, createdTime=2021-05-29, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=274d2119505a, moduleTitle=Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274d2119505a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440255, encodeId=d031144025579, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, objectType=article, longId=211375, objectId=15302113e548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15302113e548, replyNumber=0, likeNumber=47, createdTime=2021-05-17, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15302113e548, moduleTitle=JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15302113e548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440254, encodeId=35a0144025416, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, objectType=article, longId=210828, objectId=32fc21082884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32fc21082884, replyNumber=0, likeNumber=47, createdTime=2021-05-06, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32fc21082884, moduleTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32fc21082884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440253, encodeId=987a144025369, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, objectType=article, longId=207094, objectId=a84a20e094e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a84a20e094e5, replyNumber=0, likeNumber=44, createdTime=2021-02-15, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a84a20e094e5, moduleTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a84a20e094e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440252, encodeId=d3fe144025283, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, objectType=article, longId=201175, objectId=e4c42011e553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c42011e553, replyNumber=0, likeNumber=36, createdTime=2020-09-26, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c42011e553, moduleTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c42011e553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440251, encodeId=852114402511e, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, objectType=article, longId=195619, objectId=fa0e195619b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa0e195619b6, replyNumber=0, likeNumber=40, createdTime=2020-06-12, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa0e195619b6, moduleTitle=默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa0e195619b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440250, encodeId=9fd814402507a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=26, createdTime=2020-06-06, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440249, encodeId=19fc14402495b, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证, objectType=article, longId=193190, objectId=7fc8193190c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fc8193190c2, replyNumber=0, likeNumber=41, createdTime=2020-05-01, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fc8193190c2, moduleTitle=魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fc8193190c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440248, encodeId=edd71440248b3, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=叶定伟教授：替雷利珠单抗横空出世，开启国内晚期尿路上皮癌治疗新篇章, objectType=article, longId=192342, objectId=f5ae19234206, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ae19234206, replyNumber=0, likeNumber=27, createdTime=2020-04-17, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ae19234206, moduleTitle=叶定伟教授：替雷利珠单抗横空出世，开启国内晚期尿路上皮癌治疗新篇章, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ae19234206)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440247, encodeId=6e46144024e7a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应, objectType=article, longId=185696, objectId=1fd2185696f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fd2185696f8, replyNumber=0, likeNumber=28, createdTime=2020-01-06, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fd2185696f8, moduleTitle=Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fd2185696f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440246, encodeId=58e114402464b, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, objectType=article, longId=185039, objectId=2317185039ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2317185039ae, replyNumber=0, likeNumber=28, createdTime=2019-12-23, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2317185039ae, moduleTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2317185039ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440245, encodeId=437d144024558, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, objectType=article, longId=183278, objectId=22bb1832e804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22bb1832e804, replyNumber=0, likeNumber=39, createdTime=2019-11-21, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22bb1832e804, moduleTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22bb1832e804)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期尿路上皮癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌# #仑伐替尼# #帕博利珠单抗#

EUR UROL | 帕博利珠单抗伴或不伴仑伐替尼作为晚期尿路上皮癌患者的一线治疗（LEAP-011）:一项3期、随机、双盲试验

2024-02-28发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #晚期尿路上皮癌# 随着过去几年批准用于治疗局部晚期或转移性尿路上皮癌（UC）的新型药物的可用性，了解长期随访期间治疗的潜在益处和风险对于医生和患者来说是至关重要的信息。转移性膀胱癌患者的5年相对生存率约为6%。最常见的膀胱癌形式是UC，占所有病例的90%以上。对于在用程序性细胞死亡蛋白1/配体1（PD-1）抑制剂，化疗或两者治疗期间或之后经历疾病进展的局部晚期或转移性UC患者，需要新的有效治疗，特别是那些具有长期总生存期（OS）和安全性数据的治疗。

2023-09-12发表于浙江省

(审核中...)

前往app查看评论内容

#恩福单抗#（EV）加#帕博利珠单抗#治疗#晚期尿路上皮癌#

Nat Rev Clin Oncol | 恩福单抗（EV）加帕博利珠单抗治疗晚期尿路上皮癌

2023-09-06发表于上海

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌

2022-04-20

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效

2022-03-16

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Cancer Treat Rev：免疫 pk 化疗，一线治疗晚期尿路上皮癌

2022-02-21

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

The Oncologist：在使用免疫检查点抑制剂治疗的晚期尿路上皮癌患者中，身体成分可作为独立的预测和预后标志物

2021-08-10

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

晚期尿路上皮癌新疗法在 2 期临床试验中显示出前景

2021-08-05

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Lancet Oncol：3期| 派姆单抗和化疗联用或单用作为晚期尿路上皮癌的一线治疗方案的疗效对比！

2021-05-29

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

JCO：3期临床试验| 吉西他滨+顺铂联合贝伐单抗治疗晚期尿路上皮癌

2021-05-17

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌

2021-05-06

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用

2021-02-15

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗

2020-09-26

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

默克的PD-1单抗Keytruda联合化疗用于晚期尿路上皮癌，III期临床失败

2020-06-12

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2020-06-06

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证

2020-05-01

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

叶定伟教授：替雷利珠单抗横空出世，开启国内晚期尿路上皮癌治疗新篇章

2020-04-17

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Brit J Cancer：晚期尿路上皮癌中结合临床和基因组因素的模型预测对PD-1/PD-L1阻断的响应

2020-01-06

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准

2019-12-23

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌

2019-11-21

科室
- - 订阅+
  - 更多科室
工具
服务